Gene-Editing Technologies Empower Rare Disease Drug Development

Release time：

2023-03-02

As gene-editing technologies continue to mature, their application in the development of therapies for rare diseases is becoming increasingly widespread.

 　　As gene-editing technologies continue to mature, their application in the development of therapies for rare diseases is deepening. Research teams have leveraged CRISPR–Cas9 gene-editing technology to conduct precision repair studies on disease-causing genes associated with a variety of rare disorders and have successfully validated therapeutic efficacy in animal models. Building on these advances, several pharmaceutical companies have initiated relevant clinical trials to translate gene-editing technologies into clinically applicable drug products. For the patient population affected by rare diseases, this progress is highly significant, as it holds the potential to transform the current situation in which most rare diseases lack effective treatments and to open up entirely new avenues for the discovery and development of therapeutics for these conditions. 